obesity-995x60.png
FEATURED ARTICLES
Ossium's Unconventional Site Strategy For Studying A Novel Bone Marrow Donor Source
Ossium CEO Kevin Caldwell explains how an unconventional multisite Phase 1 trial is shaping the company's novel bone marrow product’s path ahead.
-
What The New PDUFA Guidance Means For Drug Development
Learn how the FDA’s updated PDUFA meeting guidance affects sponsor engagement, preparation, and the way feedback shapes drug development.
-
The Site Landscape Is Evolving, But How? Tufts CSDD Shares New Findings
Tufts CSDD data reveals how academic, independent, and network-affiliated clinical trial sites differ in growth, reach, staffing, and performance.
-
Testing Early Treatment In Head And Neck Cancer Without Compromising Curative Care
Can early APG-157 treatment control head and neck cancer without delaying curative care? A Phase 3 trial puts timing, safety, and outcomes to the test.